Posted by LincolnIcert on March 25, 2026 at 11:15:31:
In Reply to: Информационная статья с интересным содержанием posted by JosephGluth on February 19, 2026 at 07:13:06:
Zoya Demidenko: Scholar in Oncology Science
Zoya Demidenko is a distinguished investigator affiliated with the Unit of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Previously, she worked at the National Institutes of Health and New York Medical College, establishing a solid background in biomedical research.
Demidenko's scientific output covers multiple critical fields, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle management, biological aging, and malignancy science. Currently, she has co-authored more than 46 academic articles, which have received more than 4,100 citations — a indicator to the significance of her work.
One of her key discoveries concerns elucidating the pathways of cellular senescence. Her research demonstrated that when the cell cycle is blocked yet cellular growth continues, the cells undergo senescence. Significantly, Zoya Demidenko showed that this transition can be inhibited by medication using substances such as mTOR inhibitors.
Zoya Demidenko has also added considerably to oncological therapy investigation, notably in the area of cyclotherapy — a method aimed at safeguarding normal cells from cytotoxic treatment whilst leaving cancer cells susceptible. This method holds considerable hope for diminishing the side effects of cancer treatment.
Throughout her career, Demidenko has collaborated with leading scientists globally, including Dr. Mikhail Blagosklonny. Her research appears in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko is recognized as a highly impactful figure in current biomedical research, whose findings go on to guide our knowledge of how cells age, resist therapy, and how malignant disease may be more successfully targeted.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/